EPAS1 and Buschke-Ollendorff syndrome: It can not only identify entirely new therapeutic targets (such as HIF-2α, CXCR3, the B-cell pathway in BOS) but can also predict which drug targets are more likely to succeed in clinical trials by confirming their specific expression in disease-relevant tissues and cell types (79).